The positive clinical effects the authors have observed using perispinal etanercept for chronic treatment of Alzheimer's disease on an open-label basis [20,21], now for a period exceeding three years, suggest that maintenance anti-TNF-alpha treatment may have prolonged beneficial effects. Here, TNF is linked to early-onset autosomal dominant Alzheimer disease.